The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.
Patients >= 18 years old;
Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
Informed for the study and no-opposed for participation;
Affiliated with a social security scheme or in an equivalent situation.
Patients ongoing another interventional clinical trial;
Patients under guardianship or trusteeship;
Pregnancy or breastfeed;
Patients refusal.
Adult patients of Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or with an active follow-up beside dermatologist.
Cohort
Prospective
Not listed
Anti-MCPyV functionality
Anti-MCPyV functionality, including cytotoxicity, of T cells obtained after in vitro culture.
Click on the lead sponsor to view all of their trials.
Assistance Publique - Hôpitaux de Paris
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborator
